Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB) (WESIPNB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03838913|
Recruitment Status : Not yet recruiting
First Posted : February 12, 2019
Last Update Posted : February 12, 2019
Intraductal papillary neoplasm of the bile duct (IPNB) is a distinct type of biliary tumor characterised with delicate fibrovascular stalks (papillary of villous) covered at biliary epithelium. The typical pathologic feature is dramatical dilation of affected bile ducts due to obstruction by mucin production. IPNB has a better prognosis than bile duct carcinoma, but the current proposed entity contains multiple definitions or categories, thus confused in pathology.
Although mutations of several genes on IPNBs (such as GNAS, KRAS, APC, CTNNB1, and RNF43) identified in previous studies, there is still an unification at gene expression signature.
This research trial will use whole exome sequencing and subsequent bioinformatic analysis in finding causative mutations in deoxyribonucleic acid (DNA) samples from IPNBs patients.
|Condition or disease|
|Bile Duct Neoplasms Intraductal Papillary Mucinous Neoplasm|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Classification of Mutation Characteristics by Whole-Exome Sequencing (WES) in Intraductal Neoplasms of the Bile Duct (IPNB) Patients|
|Estimated Study Start Date :||February 15, 2019|
|Estimated Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||December 31, 2019|
intraductal papillary neoplasm of the bile duct
- Identification of novel genetic contributors to IPNBs [ Time Frame: 1 year ]Novel genetic abnormalities that are found to be associated with IPNBs via production-scale platform for whole exome sequencing from archival (FFPE) material. The tumor and normal specimens will be obtained from patients with IPNBs who are receiving treatment at Fujian Provincial Hospital, Fujian Medical University Union Hospital and First affiliated Hospital of Fujian Medical University.
- Validation of WES outcomes [ Time Frame: 1 year ]To precise determination of mutation signature of WES results by Sanger Sequencing.
- Determination of involved signal pathways [ Time Frame: 1 year ]To predict and verify the involved signal pathways by bioinformatics
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03838913
|Contact: Yaodong Wang, Prof||18105010560 ext email@example.com|
|Fuzhou, Fujian, China, 350001|
|Contact: Yaodong Wang 18105010560 ext 18105010560 firstname.lastname@example.org|
|Principal Investigator:||Yaodong Wang, Prof||Fujian Provincial Hospital|